Timothy P Spicer Ph.D.
- Mailing Address:
-
130 Scripps Way #1A1
The Herbert Wertheim UF Scripps Institute
Jupiter FL 33458
-
Associate Editor SLAS Discovery2020-Current · SLAS
-
SLAS Board of Directors2020-2022 · Society of Lab Automation and Screening (SLAS)
-
Member2019-2020 · SLAS Knowledge Council and Dissemination Committee
-
Co-Chair2019-2020 · SLAS Americas Scientific Program Committee
-
Member, Graduate Education Fellowship Grant Review Panel2018 · SLAS Graduate Education Fellowship Grant Review Panel-2018,2019 AACR, 2018-2020
-
Conference Co-Chair2018 · SLAS
-
SBIR Study Section Reviewer2017 · National Institutes of Health
-
Inducted2017 · SLAS Fellow
-
Inducted2017 · SLAS Fellows
-
Track Chair, Automation and HTS Technologies2016 · SLAS
-
Associate Track Chair, Automation and HTS Technologies2015 · SLAS
-
Applied Biotechnology Collaboration Award2005 · Bristol-Myers Squibb
-
Triumph Award2003 · Bristol-Myers Squibb
-
Star Award, Fourth quarter2002 · Bristol-Myers Squibb
-
Star Award, First quarter2002 · Bristol-Myers Squibb
-
Applied Biotechnology Collaboration Award2002 · Bristol-Myers Squibb
-
President’s Award2000 · Bristol-Myers Squibb
-
Excellence Award1997-2005 · Bristol-Myers Squibb
The focus of our research involves enabling technologies for High Throughput Screening (HTS) of any target of unmet therapeutic need. Our facility supports scientist and faculty locally as well as those in the US and throughout the world. We do this by implementing their biological applications into high density plates for HTS. The breadth of biology we deal with is virtually unlimited due to the diversity of skill sets of the scientist and engineers within our group as well as the expanded capability of the readers associated to our system. We operate a fully automated 1536 well compatible platform and perform HTS on large compound libraries such as the Scripps Drug Discovery Library (645K) or small focused collections (FDA approved drugs). We have expertise in microfluidics, low nanoliter volume liquid handling, ultra-sensitive plate reader technologies and informatics set-up to handle large volume data sets. Key components are high-content readers, imaging detectors such as the ViewLux and FLIPR Tetra, as well as pintool and acoustic transfer devices. Through collaborative efforts we have successfully translated multiple small molecules into the clinics. We are open to any pharmacology desired (agonist, PAMs, NAMs, inverse agonist, etc.) vs. kinases, GPCR, NHRs, proteases, phenotypic assays, etc. which can be applied to any therapeutic area; i.e. CNS, infectious diseases, cardiovascular, oncology, metabolic diseases. In addition, we are currently funded (R33CA206949) to develop 3D spheroid based uHTS assays for the purpose of testing molecules in a more phenotypically relevant format to cancer biology.
- 2024 SLAS Discovery
- 2024 Journal of medicinal chemistry
- 2024 SLAS Discovery
- 2024 SLAS Discovery
- 2024 SLAS Discovery
- 2024 SLAS Discovery
- 2023 SLAS Discovery
- 2023 SLAS Discovery
- 2023 SLAS Discovery
- 2023 Signal transduction and targeted therapy
- 2023 Cell death & disease
- 2023 bioRxiv : the preprint server for biology
- 2022 SLAS discovery : advancing life sciences R & D
- 2022 SLAS discovery : advancing life sciences R & D
-
2022
Rapid deployment of inexpensive open-source orbital shakers in support of high-throughput screening.SLAS technology
- 2022 ACS Chemical Biology
- 2022 SLAS discovery : advancing life sciences R & D
- 2022 SLAS discovery : advancing life sciences R & D
- 2022 SLAS discovery : advancing life sciences R & D
- 2022 mBio
- 2021 Bioorganic & medicinal chemistry
- 2021 SLAS Discovery
- 2021 SLAS Discovery
- 2021 PLOS Neglected Tropical Diseases
- 2021 SLAS Discovery
- 2021 Pharmaceuticals (Basel, Switzerland)
- 2021 Pharmaceuticals (Basel, Switzerland)
- 2021 Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
- 2020 The Journal of neuroscience : the official journal of the Society for Neuroscience
- 2020 Science Advances
- 2020 Scientific reports
- 2020 Nature chemical biology
- 2020 SLAS Discovery
- 2020 SLAS discovery : advancing life sciences R & D
- 2020 Molecular oncology
- 2019 SLAS Discovery
- 2019 Proceedings of the National Academy of Sciences of the United States of America
- 2019 SLAS discovery : advancing life sciences R & D
- 2019 ACS infectious diseases
- 2019 SLAS technology
- 2019 SLAS technology
- 2019 Journal of visualized experiments : JoVE
- 2019 Bioorganic & medicinal chemistry letters
- 2019 Scientific reports
- 2018 Talanta
- 2018 SLAS technology
- 2018 Molecular neuropsychiatry
- 2018 Assay and drug development technologies
- 2018 SLAS discovery : advancing life sciences R & D
- 2018 Oncotarget
-
2018
Chemical validation and optimization of pharmacoperones targeting vasopressin type 2 receptor mutantBiochemical Journal
- 2018 SLAS discovery : advancing life sciences R & D
- 2018 SLAS discovery : advancing life sciences R & D
- 2018 Oncogene
- 2018 BioProcess international
- 2018 Assay and drug development technologies
- 2018 SLAS discovery : advancing life sciences R & D
- 2017 PloS one
- 2017 SLAS discovery : advancing life sciences R & D
- 2017 SLAS discovery : advancing life sciences R & D
- 2017 Assay and drug development technologies
- 2017 SLAS discovery : advancing life sciences R & D
- 2016 eLife
- 2016 Molecular and cellular endocrinology
- 2016 Journal of biomolecular screening
- 2016 Journal of biomolecular screening
- 2016 ACS chemical biology
- 2016 Antimicrobial agents and chemotherapy
- 2016 Scientific reports
- 2016 Journal of biomolecular screening
- 2016 Assay and drug development technologies
- 2015 ACS chemical biology
- 2015 ACS chemical biology
- 2015 PloS one
- 2015 Journal of biomolecular screening
- 2015 Assay and drug development technologies
- 2015 Trends in pharmacological sciences
- 2015 Journal of biomolecular screening
- 2014 Journal of biomolecular screening
- 2014 Assay and drug development technologies
- 2014 Biopolymers
- 2014 Assay and drug development technologies
- 2014 Journal of medicinal chemistry
- 2014 Assay and drug development technologies
- 2013 Proceedings of the National Academy of Sciences of the United States of America
- 2013 Bioorganic & medicinal chemistry letters
- 2013 Bioorganic & medicinal chemistry letters
- 2013 Bioorganic & medicinal chemistry
- 2013 Bioorganic & medicinal chemistry letters
- 2013 Bioorganic & medicinal chemistry
- 2012 ACS chemical biology
- 2012 Journal of the American Chemical Society
- 2011 Journal of the American Chemical Society
- 2011 Molecular cancer therapeutics
- 2011 Journal of biomolecular screening
- 2011 Proceedings of the National Academy of Sciences of the United States of America
- 2011 Journal of the American Chemical Society
- 2011 Molecular and biochemical parasitology
- 2010 Molecular pharmacology
- 2010 Bioorganic & medicinal chemistry letters
- 2010 ACS medicinal chemistry letters
- 2010 Assay and drug development technologies
- 2009 Bioorganic & medicinal chemistry
- 2009 Bioorganic & medicinal chemistry letters
- 2009 Bioorganic & medicinal chemistry letters
- 2009 Bioorganic & medicinal chemistry letters
- 2008 Analytical biochemistry
- 2008 ACS chemical biology
- 2008 Journal of biomolecular screening
- 2003 Journal of medicinal chemistry
- 2003 Drug discovery today
- 2003 Proceedings of the National Academy of Sciences of the United States of America
- 2000 Antimicrobial agents and chemotherapy
-
2019
Ph.D. in MedicineUniversity of Queensland
-
1996
Master's of MicrobiologyState University of New York Health Science Center
-
1990
Bachelor's of Science in BiologyState University of New York at Albany
Jatinder Lamba Ph.D., M.Sc.
- Mailing Address:
-
PO BOX 103633
GAINESVILLE FL 32610
- Physical Address:
-
2033 MOWRY RD
GAINESVILLE FL 32610
Dr. Jatinder Lamba is currently the associate dean for research and graduate education in the UF College of Pharmacy and a professor in the Department of Pharmacotherapy and Translational Research. In 2022, she was appointed the Frank A. Duckworth Eminent Scholar Chair.
Lamba did her post-doctoral training at St. Jude Children’s Research Hospital in Memphis, Tennessee. Prior to joining University of Florida, she was an Associate Professor at University of Minnesota, Department of Experimental and Clinical Pharmacology, College of Pharmacy and the Director of the Pathway driven Pharmacogenomics; University of Minnesota Alliance (PUMA) Institute of Personalized Medicine.
Dr Lamba’s research is focused on identification, characterization and clinical validation of genomic/epigenomic markers predictive of therapeutic outcome in cancer patients. This research spans from preclinical basic research comprising the discovery phase utilizing cell line model systems to translational/clinical phase in patient populations from multi-institute clinical trials. The long-term goal of her research is to move pharmacogenetic testing into the clinical setting to improve safety and efficacy of drug therapy. Dr. Lamba’s research on pharmacogenomics of anti-leukemic agents has been funded by NIH/NCI since 2008. Specifically, her current NCI funded R01 focuses on pharmacogenomics/ epigenomics of cytarabine (ara-C), a nucleoside analog that is the backbone of anti-leukemia chemotherapy in pediatric AML patients. Her group is working on developing algorithms to incorporate pharmacogenomics/epigenomic markers with other prognostic factors to advance precision medicine in oncology. Identification of such patients upfront will provide opportunity to tailor the initial chemotherapy to achieve maximum benefit.
Dr. Lamba’s lab is the first one to identify genetic polymorphisms in CD33 gene that are predictive of response to CD33 targeted agents in AML. These results hold promise in utilizing preemptive genotype to select patients most likely to benefit from CD33-directed therapy such as gemtuzumab ozogamicin in treating AML. Previous work on CD33 genomics was funded by NCI and more in-depth characterization of CD33 as AML therapeutic target is funded by a recent award from leukemia Lymphoma Society.
Given a critical gap of our understanding in metabolic dysregulation in AML, Dr. Lamba’s group is focused understanding the metabolomics differences and biomarkers of prognostic significance in pediatric AML. Dr. Lamba’s recent work is focused towards utilizing transcriptomics to build and refine leukemic stem cell signatures and AML drug response signatures of prognostic and predictive value in AML.
Dr. Lamba has served as chair of Pharmacogenomics SIG at AACP (2013) and is currently vice-chair of Pharmacogenomics focus group with AAPS. She has served as a grant reviewer for numerous NIH study sections and has reviewed grants for international agencies as Italian Ministry of Health. She has published more than 90 research articles in peer-reviewed journals and is on the editorial boards of Leukemia and Lymphoma, Pharmacogenomics and Frontiers in Pharmacogenomics and genomics, JCMM. Dr. Lamba is currently Professor in College of Pharmacy and is also Graduate Program coordinator for PTR department. Dr. Lamba is very committed towards training of future generation of scientist. She has trained 6 Ph. D students, 5 Post-doctoral fellows several Pharm D students and 3 hematology-oncology fellows and several under-graduate students including minority and underrepresented students.
- 2024 JAMA network open
- 2024 Clinical Cancer Research
- 2024 npj Precision Oncology
- 2024 Clinical Cancer Research
- 2024 bioRxiv : the preprint server for biology
- 2023 Blood Advances
- 2023 JCO Precision Oncology
- 2023 Haematologica
- 2023 Pharmacogenomics
- 2023 Blood Advances
- 2023 Pediatric blood & cancer
- 2023 Cancers
- 2022 Frontiers in oncology
- 2022 Haematologica
- 2022 Pharmaceutics
- 2022 Journal of Clinical Oncology
- 2022 Leukemia
- 2021 Haematologica
- 2021 Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
- 2021 Journal of pediatric hematology/oncology
- 2021 Future Oncology
- 2021 Blood Cancer Discovery
- 2021 Cancers
- 2021 Clinical pharmacology and therapeutics
- 2021 Clinical and translational science
- 2021 Frontiers in oncology
- 2021 BMC medical education
- 2020 Pharmacogenetics and genomics
- 2020 American journal of hematology
- 2020 Cancers
- 2020 Cancers
- 2020 Leukemia
- 2020 Leukemia
- 2020 Leukemia
- 2019 Cell metabolism
- 2019 Bone
- 2019 Genes
- 2019 JCO precision oncology
- 2019 Leukemia & lymphoma
- 2019 Blood Cancer Journal
- 2019 Blood Advances
- 2018 Oncotarget
- 2018 Oncotarget
- 2018 Future oncology (London, England)
- 2018 Scientific reports
- 2018 Oncotarget
- 2018 Pharmacogenomics
- 2018 Leukemia & lymphoma
- 2017 Journal of clinical pharmacy and therapeutics
- 2017 Leukemia research
- 2017 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2016 Frontiers in genetics
- 2016 Oncotarget
- 2016 Leukemia & lymphoma
- 2016 BMC bioinformatics
- 2015 Frontiers in pharmacology
- 2015 BMC genomics
- 2015 Pharmacogenomics
- 2015 Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
- 2014 British journal of cancer
- 2014 Pharmacogenetics and genomics
- 2014 BMC research notes
- 2014 Pharmacogenomics
- 2014 American journal of hematology
- 2013 Pharmacogenetics and genomics
- 2013 Pharmacogenomics
- 2013 Blood
- 2013 Clinical cancer research : an official journal of the American Association for Cancer Research
- 2013 Pharmacogenomics
- 2012 Journal of biomedical informatics
- 2012 Pharmacogenetics and genomics
- 2012 Pharmacogenetics and genomics
- 2012 Pharmacogenomics
- 2012 Biochemical pharmacology
- 2012 Mayo Clinic proceedings
- 2012 Pharmacogenomics
- 2012 Naunyn-Schmiedeberg's archives of pharmacology
- 2012 Pharmacogenomics
- 2011 Clinical pharmacology and therapeutics
- 2011 Pharmacogenomics
- 2011 Leukemia
- 2011 Pharmacogenomics
- 2011 The Journal of pharmacology and experimental therapeutics
- 2011 The Journal of biological chemistry
- 2010 Pharmacogenetics and genomics
- 2010 The Journal of pharmacology and experimental therapeutics
- 2009 Bioinformatics (Oxford, England)
- 2009 Blood
- 2009 Pharmacogenomics
- 2009 Leukemia
- 2008 Drug metabolism and disposition: the biological fate of chemicals
- 2008 Pharmacogenomics
- 2008 Drug metabolism and disposition: the biological fate of chemicals
- 2008 Drug metabolism and disposition: the biological fate of chemicals
- 2007 The Journal of pharmacology and experimental therapeutics
- 2007 Pharmacogenomics
- 2006 Journal of acquired immune deficiency syndromes (1999)
- 2006 Clinical pharmacology and therapeutics
- 2006 Pharmacogenetics and genomics
- 2006 Journal of clinical pharmacology
- 2006 The Journal of pharmacology and experimental therapeutics
- 2005 Clinical pharmacology and therapeutics
- 2005 Transplant immunology
- 2005 Journal of clinical pharmacology
- 2005 Current drug metabolism
- 2004 Pediatric transplantation
- 2004 Journal of clinical pharmacology
- 2004 Toxicology and applied pharmacology
- 2004 Pharmacological reviews
- 2004 The Journal of pharmacology and experimental therapeutics
- 2003 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
- 2003 Human molecular genetics
- 2003 Pharmacogenetics
- 2003 The Journal of pharmacology and experimental therapeutics
- 2003 Journal of applied physiology (Bethesda, Md. : 1985)
- 2002 Human immunology
- 2002 Advanced drug delivery reviews
- 2002 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2002 Pharmacogenetics
- 2001 Nature genetics
- 2001 The Journal of biological chemistry
- 2000 Clinical pharmacology and therapeutics
- 1998 Clinical pharmacology and therapeutics
-
Sep 2023
ACTIVE
2/3 Florida-California Cancer Research, Education & Engagement (CaRE2) Health Equity CenterNATL INST OF HLTH NCI · Other
-
Sep 2023
ACTIVE
CRISPR Synthetic Lethality Screen Identifies Genomic Resistant/Sensitive Modulators of Standard Chemotherapy in Pediatric Acute Myeloid Leukemia (pAML)AMER FOU FOR PHARM EDU · Other
-
Apr 2023
ACTIVE
Targeting ER Stress in Pediatric Acute Myeloid LeukemiaH LEE MOFFITT CANCER CTR & RES INST · Principal Investigator
-
Dec 2022
ACTIVE
Integrated Systems Biology of Pediatric AMLNATL INST OF HLTH NCI · Principal Investigator
-
Sep 2022
ACTIVE
The role of ALKBH5-mediated RNA demethylation in the maintenance of genomic stability in HSPCsNATL INST OF HLTH NIDDK · Co-Investigator
-
May 2022
ACTIVE
Patterns of resistance to initial therapeutic treatment in Ewings SarcomaHematology/Oncology Pharmacy Asso Fou · Co-Investigator
-
Apr 2022
ACTIVE
Ultrasound elastogram assessment of liver fibrosis in children and adolescents/young adults (AYA) receiving chemotherapy or allogeneic bone marrow transplantation, and identification of risk factors for liver injuryFL DEPT OF HLTH LIVE LIKE BELLA · Other
-
Jul 2021
ACTIVE
Genomics of AML PrognosisNATL INST OF HLTH NCI · Principal Investigator
-
Jul 2021
–
Dec 2023
Transcriptomic and pharmacogenetic scores to guide therapy in pediatric AMLAMERICAN CANCER SOCIETY · Principal Investigator
-
Sep 2020
–
Aug 2021
Pharmacogenomic Drivers of Efficacy in Anti-CD33 Immunotherapeutic Treatment StrategiesAMER FOU FOR PHARM EDU · Other
-
Sep 2020
–
Aug 2021
AFPE Fellowship: Rho Chi -AFPE Graduate FellowshipAMER FOU FOR PHARM EDU · Other
-
Aug 2020
–
Jul 2021
Pharmacokinetics and Pharmacogenomics of Pediatric ChemotherapeuticsUNIV OF CALIFORNIA SAN FRANCISCO · Principal Investigator
-
Jan 2020
–
Dec 2023
Asparaginase Premedication, Hypersensitivity, and Therapeutic Drug Monitoring in Pediatric Patients with Acute Lymphoblastic Leukemia or LymphomaSERVIER PHARMACEUTICALS · Principal Investigator
-
Jul 2019
–
Jun 2020
Personalizing CD33-directed immunotherapy for pediatric AMLCHILDRENS ONCOLOGY GROUP · Principal Investigator
-
Jul 2019
–
Jun 2022
Personalizing CD33-directed Immunotherapy for Pediatric AMLLEUKEMIA & LYMPHOMA SOC · Principal Investigator
-
Apr 2019
–
Mar 2022
Pharmacogenomics and Toxicities of Thiotepa, Busulfan and Fludarabine in Pediatric HSCT RecipientsFL DEPT OF HLTH LIVE LIKE BELLA · Principal Investigator
-
Jun 2018
–
May 2021
OR-DRPD-ROD2018: Development of Leukemia-Oncotype Prototype CARS (Cytarabine AML Response Score) for Prediction of Relapse Risk in AMLUF RESEARCH · Principal Investigator
-
Feb 2018
–
Jan 2019
Impact of CD33 Genetics on Clinical Outcome in Pediatric AML Patients Treated on AAML0531 Clinical TrialCHILDRENS ONCOLOGY GROUP · Principal Investigator
-
Dec 2016
–
Jan 2020
Multiple SponsorsMULTIPLE SPONSORS · Principal Investigator
-
Jan 2015
–
Jan 2016
DNA ISOLATION/GENOTYPING COLLABORATIONUNIV OF MINNESOTA · Principal Investigator
-
Sep 2014
–
Apr 2020
Pharmacogenomics of Ara-C in AMLNATL INST OF HLTH NCI · Principal Investigator
-
Jul 2014
–
Dec 2015
Impact of genetic variation on response to GO therapy in COG-AML clinical trialsNATL INST OF HLTH NCI · Principal Investigator
-
Published
March 2023
CD33 Antibodies#US-2023-0365676-A1
-
Published
March 2022
Methods for Predicting AML Outcome#20230073558A1
-
2000
Ph.D.Postgraduate Institute of Medical Education and Research
-
1994
M.Sc.Postgraduate Institute of Medical Education and Research
-
1992
B.Sc.Panjab University